Primary prevention of cancer-related thrombosis: Special focus on ambulatory patients

      The incidence of venous thromboembolism (VTE) in cancer patients is overall increased by 4 to 6.5 fold compared to the general population and affects up to 20% of patients with cancer, and represents a leading cause of death in this population [
      • Chew H.K.
      • Wun T.
      • Harvey D.
      • Zhou H.
      • White R.H.
      Incidence of venous thromboembolism and its effect on survival among patients with common cancers.
      ]. However, individual VTE risk in cancer subjects widely varies depending on the specific patient-, treatment-, and cancer-related factors [
      • Mandala M.
      • Clerici M.
      • Corradino I.
      • et al.
      Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the ‘SENDO experience’.
      ].

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to International Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Chew H.K.
        • Wun T.
        • Harvey D.
        • Zhou H.
        • White R.H.
        Incidence of venous thromboembolism and its effect on survival among patients with common cancers.
        Arch Intern Med. 2006; 166: 458-464
        • Mandala M.
        • Clerici M.
        • Corradino I.
        • et al.
        Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the ‘SENDO experience’.
        Ann Oncol. 2012; 23: 1416-1421
        • Khorana A.A.
        • Streiff M.B.
        • Farge D.
        • et al.
        Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action.
        J Clin Oncol. 2009; 27: 4919-4926
        • Khorana A.A.
        • Kuderer N.M.
        • Culakova E.
        • Lyman G.H.
        • Francis C.W.
        Development and validation of a predictive model for chemotherapy-associated thrombosis.
        Blood. 2008; 111: 4902-4907
        • Moore R.A.
        • Adel N.
        • Riedel E.
        • et al.
        High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis.
        J Clin Oncol. 2011; 29: 3466-3473
        • Ay C.
        • Dunkler D.
        • Marosi C.
        • et al.
        Prediction of venous thromboembolism in cancer patients.
        Blood. 2010; 116: 5377-5382
        • Ay C.
        • Simanek R.
        • Vormittag R.
        • et al.
        High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS).
        Blood. 2008; 112: 2703-2708